Search

Recursion Pharmaceuticals Inc

Fechado

SetorSaúde

3.28 -8.12

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.5300000000000002

Máximo

3.58

Indicadores-chave

By Trading Economics

Rendimento

-9.4M

-118M

Vendas

-29M

6.5M

EPS

-0.22

Margem de lucro

-1,815.575

Funcionários

600

EBITDA

-13M

-102M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+107.3% upside

Dividendos

By Acuity

Próximos Ganhos

4 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

234M

2.1B

Abertura anterior

11.4

Fecho anterior

3.28

Sentimento de Notícias

By Acuity

50%

50%

147 / 342 Ranking em Healthcare

Recursion Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jul. de 2026, 23:06 UTC

News

PepsiCo shares are lower in after-market hours following a downgrade to Hold by Citi, with the price target reduced to $145 from $170.

10 de jul. de 2026, 23:01 UTC

News

Cognizant Technology Solutions received court approval for a $5.5 million settlement in a stockholder lawsuit, with shares trading higher in after-market hours.

10 de jul. de 2026, 20:13 UTC

ETF Constituents
News
Correlated Moves

Vanguard Large-Cap ETF is trading lower in after-market hours, influenced by slight losses in top holdings META, AAPL, ABBV, MA, and NVDA.

10 de jul. de 2026, 20:07 UTC

News
Correlated Moves

Ethereum is gaining as Circle Internet Group receives approval for a national trust bank, boosting interest in digital assets amid geopolitical tensions.

10 de jul. de 2026, 20:07 UTC

News

Costco Wholesale shares are higher today, recovering from earlier losses despite concerns over moderating growth and sustainability amid easing fuel prices.

10 de jul. de 2026, 20:07 UTC

News
Social Media

Micron Technology shares are lower amid a semiconductor sector selloff, despite announcing over $250 billion in U.S. investment for AI memory chips.

10 de jul. de 2026, 20:07 UTC

News
Social Media
Event

Netflix Inc shares are lower amid concerns about declining subscriber engagement. The company is exploring strategies to enhance viewer interest, including live TV channels.

10 de jul. de 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher as Circle Internet Group gains approval for a national trust bank focused on digital asset custody services. Ethereum also shows notable increases.

10 de jul. de 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher since Thursday's close, supported by Circle Internet Group's approval for a national trust bank focused on digital asset custody services.

10 de jul. de 2026, 20:07 UTC

Correlated Moves
News

Ethereum is gaining amid increased market interest following Circle Internet Group's trust bank approval. Geopolitical tensions are also driving investors toward cryptocurrencies.

10 de jul. de 2026, 20:06 UTC

News

Autodesk Inc shares are lower today following a negative report from StockStory, which advises avoiding the stock due to slower revenue growth and high payback periods.

10 de jul. de 2026, 20:06 UTC

News

United Airlines shares are lower amid concerns following Delta's strong earnings report, which raised expectations for upcoming results but highlighted pricing power challenges.

10 de jul. de 2026, 20:06 UTC

Correlated Moves
Social Media
News

Applied Materials shares advance as Needham raises price target to $740 and Stifel lifts its target to $650, reflecting strong demand in the semiconductor sector.

10 de jul. de 2026, 20:03 UTC

News
Social Media

NVIDIA shares are higher today as Morgan Stanley reaffirms its Overweight rating and U.S. eases AI chip export curbs to the UAE.

10 de jul. de 2026, 20:02 UTC

News

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

10 de jul. de 2026, 20:02 UTC

News
Social Media

Fox Corp shares are higher, supported by record FIFA World Cup viewership and an upgrade to Buy from Rothschild Redburn, raising the price target to $71.

10 de jul. de 2026, 20:01 UTC

News

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

10 de jul. de 2026, 19:56 UTC

Social Media
News

Dollar Tree shares are higher after a positive UBS assessment, signaling an inflection point for the retailer amid cautious market sentiment ahead of key economic data.

10 de jul. de 2026, 19:51 UTC

Social Media
News

Take-Two Interactive is under pressure amid sector weakness, with a recent report advising against the stock due to limited cash flow and declining sales projections.

10 de jul. de 2026, 19:47 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Small-Cap ETF is lower amid ongoing geopolitical tensions and declines among key holdings, including SRPT, AXON, NTRA, LAMR, and IONS.

10 de jul. de 2026, 19:47 UTC

News
Social Media

Tesla Inc's stock is higher, supported by increased buying interest and strong Model Y sales in China, with shares reaching an intraday high of $407.85.

10 de jul. de 2026, 19:47 UTC

News

PayPal Holdings Inc is gaining momentum, driven by strong performance in Venmo and Braintree, alongside a clearer operational framework under CEO Dan Schulman.

10 de jul. de 2026, 19:47 UTC

News
Social Media

Intel Corp's stock is lower as AMD's data center revenue outpaces Intel's, raising investor concerns amid ongoing profitability challenges.

10 de jul. de 2026, 19:47 UTC

News

Qualcomm shares are lower at about $188.81 amid mixed options sentiment and a decline in implied volatility ahead of the upcoming earnings report.

10 de jul. de 2026, 19:47 UTC

Correlated Moves
Social Media
News

Broadcom shares are lower despite a $30 billion agreement with Apple to produce custom silicon components through 2031, amid broader semiconductor industry concerns.

10 de jul. de 2026, 19:46 UTC

News
Social Media

Rothschild Redburn upgraded Fox Corp to Buy, raising the price target to $71. The stock remains higher since Thursday's close despite earlier session pullbacks.

10 de jul. de 2026, 19:46 UTC

News

American Airlines Group faces challenges ahead of its earnings report, with shares declining amid cautious sentiment following Delta Air Lines' strong Q2 performance.

10 de jul. de 2026, 19:41 UTC

Macro News
ETF Constituents
News

FXI is trading higher following Shein's Hong Kong IPO approval, boosting confidence in Chinese equities. Key holdings XIACY and TCOM also show notable returns.

10 de jul. de 2026, 19:36 UTC

News

CSX shares rise on TD Cowen, JP Morgan upgrades ahead of Q2 report.

10 de jul. de 2026, 19:36 UTC

News
Social Media

Microsoft shares advanced after Argus reaffirmed a Buy rating, lowering the price target to $510. The stock remains near the upper end of its one-month range.

Comparação entre Pares

Variação de preço

Recursion Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

107.3% parte superior

Previsão para 12 meses

Média 7.38 USD  107.3%

Máximo 10 USD

Mínimo 5.5 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Recursion Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

2

Comprar

3

Manter

0

Vender

Sentimento

By Acuity

147 / 342 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat